Clinical Trial Update: An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

An open-label, single-arm Phase 2 trial evaluating Stapokibart in combination with tislelizumab for non-small cell lung cancer, with status NOT_YET_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Stapokibart
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sichuan University | Conditions: Lung Cancer (NSCLC) | Phase 2 | Status: NOT_YET_RECRUITING